Cancer Res Treat.  2020 Oct;52(4):1199-1210. 10.4143/crt.2020.303.

High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China

• Sun L
• Hu W
• Liu M
• Chen Y
• Jin B
• Xu H
• Du S
• Xu Y
• Zhao H
• Lu X
• Sang X
• Zhong S
• Yang H
• Mao Y

• KMID: 2507945
• DOI: http://doi.org/10.4143/crt.2020.303

Abstract

Purpose
The systemic inflammation response index (SIRI) has been reported to have prognostic ability in various solid tumors but has not been studied in gallbladder cancer (GBC). We aimed to determine its prognostic value in GBC.
Materials and Methods
From 2003 to 2017, patients with confirmed GBC were recruited. To determine the SIRI’s optimal cutoff value, a time-dependent receiver operating characteristic curve was applied. Univariate and multivariate Cox analyses were performed for the recognition of significant factors. Then the cohort was randomly divided into the training and the validation set. A nomogram was constructed using the SIRI and other selected indicators in the training set, and compared with the TNM staging system. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram’s clinical utility.
Results
One hundred twenty-four patients were included. The SIRI’s optimal cutoff value divided patients into high (≥ 0.89) and low SIRI (< 0.89) groups. Kaplan-Meier curves according to SIRI levels were significantly different (p < 0.001). The high SIRI group tended to stay longer in hospital and lost more blood during surgery. SIRI, body mass index, weight loss, carbohydrate antigen 19-9, radical surgery, and TNM stage were combined to generate a nomogram (C-index, 0.821 in the training cohort, 0.828 in the validation cohort) that was significantly superior to the TNM staging system both in the training (C-index, 0.655) and validation cohort (C-index, 0.649).
Conclusion
The SIRI is an independent predictor of prognosis in GBC. A nomogram based on the SIRI may help physicians to precisely stratify patients and implement individualized treatment.

Keyword

Gallbladder neoplasms; Systemic inflammation response index (SIRI); Overall survival; Prognosis; Nomogram

Figure

• 

  Fig. 1. Time-dependent receiver operating characteristic (ROC) analysis of systemic inflammation response index (SIRI) for 1-, 3-, and 5-year survival. AUC, area under the curve.

• 

  Fig. 2. Kaplan-Meier survival curves of different systemic inflammation response index (SIRI) groups.

• 

  Fig. 3. Time-dependent receiver operating characteristic analysis of each of the selected factors and the prognostic model. SIRI, systemic inflammation response index; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; AUC, area under the curve.

• 

  Fig. 4. Prognostic nomogram for predicting 1-, 3-, and 5-year overall survival probability based on the systemic inflammation response index (SIRI) group, body mass index (BMI), weight loss, carbohydrate antigen 19-9 (CA19-9), radical surgery, and TNM stage in patients with gallbladder cancer.

• 

  Fig. 5. Nomogram calibration plot for predicting overall survival probabilities at 1 year (A, C) and 3 years (B, D).

• 

  Fig. 6. Decision curve analysis (DCA) of the model and TNM staging system for 1- (A, B), 3- (C, D), and 5-year (E, F) overall survival (OS).

• 

  Fig. 7. Histograms of nomogram-predicted probability of 12-month survival according to the different American Joint Committee on Cancer TNM stage groupings.

Reference

References

1. de Aretxabala X. Biliary spillage a new prognostic factor in gallbladder cancer? Hepatobiliary Surg Nutr. 2019; 8:537–8.

2. Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides GA, et al. Changing odds of survival over time among patients undergoing surgical resection of gallbladder carcinoma. Ann Surg Oncol. 2016; 23:4401–9.

3. Wi Y, Woo H, Won YJ, Jang JY, Shin A. Trends in gallbladder cancer incidence and survival in Korea. Cancer Res Treat. 2018; 50:1444–51.

4. Fortner JG, Pack GT. Clinical aspects of primary carcinoma of the gallbladder. AMA Arch Surg. 1958; 77:742–50.

5. Sung YN, Song M, Lee JH, Song KB, Hwang DW, Ahn CS, et al. Validation of the 8th edition of the American Joint Committee on Cancer staging system for gallbladder cancer and implications for the follow-up of patients without node dissection. Cancer Res Treat. 2020; 52:455–68.

6. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15:e493–503.

7. Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget. 2017; 8:2329–41.

8. Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016; 122:2158–67.

9. Li S, Lan X, Gao H, Li Z, Chen L, Wang W, et al. Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. J Cancer Res Clin Oncol. 2017; 143:2455–68.

10. Geng Y, Zhu D, Wu C, Wu J, Wang Q, Li R, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018; 65:503–10.

11. Chen Y, Jiang W, Xi D, Chen J, Xu G, Yin W, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med. 2019; 67:691–8.

12. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67:93–9.

13. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26:565–74.

14. General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014; 81:14–8.

15. Narayan RR, Creasy JM, Goldman DA, Gonen M, Kandoth C, Kundra R, et al. Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations. Cancer. 2019; 125:575–85.

16. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34.

17. Margonis GA, Gani F, Buettner S, Amini N, Sasaki K, Andreatos N, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB (Oxford). 2016; 18:872–8.

18. Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019; 68:1024–33.

19. Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, et al. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019; 8:604–14.

20. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20:663–73.

21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74.

22. Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. Baseline and trend of lymphocyte-to-monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One. 2015; 10:e0136252.

23. Cheng H, Luo G, Lu Y, Jin K, Guo M, Xu J, et al. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 2016; 16:1080–4.

24. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176–81.

25. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001; 411:380–4.

26. Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, et al. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study. BMC Cancer. 2017; 17:404.

27. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344:921–5.

28. Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013; 144:1031–41.

29. Bai Y, Liu ZS, Xiong JP, Xu WY, Lin JZ, Long JY, et al. Nomogram to predict overall survival after gallbladder cancer resection in China. World J Gastroenterol. 2018; 24:5167–78.

30. Chen M, Lin J, Cao J, Zhu H, Zhang B, Wu A, et al. Development and validation of a nomogram for survival benefit of lymphadenectomy in resected gallbladder cancer. Hepatobiliary Surg Nutr. 2019; 8:480–9.